Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism
Abstract
Objective To evaluate the effects of liquid (drops) and tablet formulations of levothyroxine in homogeneous groups of infants with congenital hypothyroidism (CH) as diagnosed through neonatal screening.Study design Forty-two consecutive infants with CH were subdivided into 2 groups consisting of infants with the severe or the moderate/mild form. For each form, the infants with CH were randomly assigned to receive liquid (group 1) or tablet (group 2) formulation. In all patients, thyroid function tests were performed before the beginning of therapy and at 15 and 30 days and at 3 and 6 months after the beginning of therapy.Results In the severe form, after 15 days of treatment, serum thyrotropin (TSH) levels became normal in 8 of 9 patients in group 1 and in 5 of 9 patients in group 2; serum free triiodothyronine (fT3) levels were significantly higher in group 1 than in group 2; and serum fT4 levels were higher than the upper limit of the normal range in all patients in both groups. During the follow-up, there were significantly more patients with suppressed TSH concentrations in group 1 than in group 2. In the moderate/mild form, the patients of group 1 and group 2 showed median values of TSH, fT3, and fT4 that were not significantly different. No clinical or electrocardiographic signs of heart disease were found. There were no significant differences in the developmental quotient between group 1 and group 2 patients with severe and moderate/mild CH.Conclusions Our data seem to indicate that there is not complete bioequivalence between drops and tablets, especially in infants with severe CH.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In hypothyroid infants and children, liquid solution LT4 shows good performance and some advantages compared with tablet preparation.
“The use of LS showed a good performance in patients of this age group and some advantages with respect to the tablet preparation (132, 133).”
From ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism (2025) · cites this paper as [133]
Taken together, liquid solutions have higher absorption, faster Tmax, and lower and more stable TSH levels than solid formulations, partially due to better intestinal absorption.
“Taken together, these results show that liquid solutions have higher absorption, faster Tmax, and lower and more stable TSH levels than solid formulations, partially due to better intestinal absorption.”
From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [188]
Studies of patients with congenital hypothyroidism revealed a more suppressed TSH level in infants receiving the LT4 solution.
“Studies of patients with congenital hypothyroidism revealed a more suppressed TSH level in infants receiving the LT4 solution (188, 189).”
From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [188]
CH patients treated with liquid LT4 may need more frequent fT4 and TSH measurements, and dose adjustments during their first months of life.
“In addition, CH patients treated with liquid LT4 may need more frequent fT4 and TSH measurements, and dose adjustments during their first months of life (92,93).”
The citation lists haven’t been fetched yet
References 29 · Cited by 68
- Authors
- Cassio, A., Monti, S., Rizzello, A., Bettocchi, I., Baronio, F., D'Addabbo, G., Bal, M. O., & Balsamo, A.
- Affiliations
- University of Bologna (IT)
- Corresponding author
- Cassio, Alessandra
- Venue
- The Journal of Pediatrics
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 162
- Issue
- 6
- Pages
- 1264-1269.e2
- ISSN
- 0022-3476 (ISSN-L)
- OpenAlex
- W1967340883
- Cited by
- 68
- References
- 29
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 2 · 2022: 5 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 5 · 2017: 8 · 2016: 8 · 2015: 7 · 2014: 6 · 2013: 4
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- The Journal of Pediatrics (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- congenital hypothyroidism, levothyroxine, liquid formulation, tablet formulation, bioequivalence, infants, thyroid function tests, TSH suppression, free triiodothyronine, free thyroxine, newborn screening, developmental quotient
- MeSH terms
- Chemistry, Pharmaceutical, Congenital Hypothyroidism, Female, Humans, Infant, Infant, Newborn, Male, Tablets, Thyroid Function Tests, Thyrotropin, Thyroxine, Triiodothyronine, Neonatal Screening, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review